What Regenity does

Regenity Biosciences is a privately held regenerative medicine company headquartered in Paramus, New Jersey, that designs, manufactures, and supplies bioresorbable medical devices and biomaterials to medical device OEMs and clinicians across eight therapeutic areas: dental, spine, orthopedics, neurosurgery, advanced wound care, sports medicine, ENT, and peripheral nerve repair. Founded in 1997 as Collagen Matrix, Inc. and rebranded in 2023 following the Polyganics acquisition, the company operates from five ISO 13485- and MDSAP-certified manufacturing facilities totaling more than 170,000 square feet across New Jersey and Groningen, Netherlands, producing 5 million+ devices annually for customers in 80+ countries.

Regenity's technology platform spans four core pillars: reconstituted and crosslinked collagen (xenograft), bioceramics and mineral-collagen composites, synthetic bioresorbable polymers, and hybrid polymer-collagen composites, supported by 100+ patents and 170+ regulatory approvals (63 FDA 510(k) clearances, 24 CE marks, 5 China MDRCs). The portfolio includes branded products such as Matrixflex, MatrixDerm, MatrixOss, OssiMend, RejuvaKnee (the first FDA-cleared regenerative meniscal implant), DuraMatrix, Neuroflex, NEUROLAC, NEUROCAP, and LIQOSEAL, alongside custom contract development and manufacturing (CDMO) services delivered on a concept-to-commercialization timeline of under two years.

The company monetizes through two complementary channels: (1) private-label/OEM product sales to medical device companies, where Regenity's proprietary components are rebranded and commercialized by partners, and (2) end-to-end CDMO engagements spanning R&D, regulatory support, process engineering, and commercial-scale manufacturing. Go-to-market is primarily direct enterprise field sales augmented by trade-show presence (MD&M West, MEDICA, Society for Biomaterials). Exclusive arrangements such as the MiMedx manufacturing and supply agreement exemplify the OEM/white-label model. Regenity is controlled by private-equity sponsors Linden Capital Partners (since ~2020) and Cinven (added February 2026).

Name

Regenity

Legal name

Collagen Matrix, Inc.

Website

https://regenity.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Regenity Biosciences is a privately held regenerative medicine company that designs, manufactures, and supplies bioresorbable collagen and polymer medical devices, plus end-to-end CDMO services, to medical device OEMs and clinicians across dental, spine, neurosurgery, nerve repair, and wound care.

Ownership category

akta.pro rank

Product category

Regenerative Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Dental Equipment and Supplies Manufacturing (339114), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Regenerative medical devices
• Bioresorbable biomaterials
• Bone graft substitutes
• Tissue regeneration implants
• Medical device CDMO

Headquarters

HQ city

Paramus

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Private Label Product Sales: Regenity sells its proprietary collagen and polymer-based regenerative medical devices to OEM customers through private label arrangements. Products include dental membranes, bone grafts, dural repair products, nerve repair devices, and orthopedic implants.
2. CDMO Services: Contract Development and Manufacturing services providing end-to-end support from R&D through regulatory, process engineering, and commercial-scale manufacturing. Regenity supports medtech partners from early feasibility through full commercialization.
3. Dental Products: Collagen dental membranes, bone graft substitutes, and wound dressings sold to dental device companies and clinicians. Products include Matrix*flex™, MatrixDerm®, MatrixMem™, MatrixOss™, SynOss™, GUIDOR®, and Collatene™.
4. Spine & Orthopedic Products: Xenograft mineral and collagen composite matrix bone graft substitutes, resorbable collagen wraps, and meniscal repair implants including RejuvaKnee™, OssiMend®, and TenoMend™.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Regenity Biosciences manufactures and sells proprietary bioresorbable medical devices—collagen, mineral, and synthetic polymer-based membranes, bone graft substitutes, dural repair patches, nerve repair conduits, and meniscal implants—primarily as private-label products to medical device OEMs, while also providing end-to-end contract development and manufacturing (CDMO) services for regenerative medical devices from R&D through regulatory clearance and commercial-scale production.

Product overview

Regenity Biosciences is a regenerative medicine company offering a comprehensive portfolio of bioresorbable medical devices for tissue and bone regeneration. The company's product portfolio is organized into four main categories: Dental (collagen dental membranes, bone graft substitutes including Matrix*flex*™, MatrixDerm®, MatrixOss™, SynOss™, GUIDOR®, Collatene™), Dural Repair & Closure (collagen-based dural repair membranes including DuraMatrix® family and LIQOSEAL®), Spine & Orthopedics (bone graft substitutes including OssiMend® family and meniscal repair implant RejuvaKnee™), and Nerve Repair (collagen and synthetic nerve conduits and wraps including Neuroflex®, NEUROLAC®, NEUROCAP®, NeuroMatrix®, NeuroMend, and VIVOSORB®). Regenity also offers end-to-end contract development and manufacturing (CDMO) services for bioresorbable medical devices. The company was founded in 1997 as Collagen Matrix, Inc. and rebranded to Regenity Biosciences in 2022 after acquiring Polyganics. Technology platforms include collagen-derived technologies, bioceramic technologies, biocomposite technologies, and synthetic polymer technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Matrix*flex™ A strong, regenerative crosslinked collagen dental membrane manufactured from purified porcine peritoneum tissue, used for guided tissue and bone regeneration in dental surgery.
• MatrixDerm® Family Regenerative collagen dental membranes, nonfriable matrices, absorbent wound dressings, and membrane caps used for oral surgical repairs, extraction sockets, denture sores, oral ulcers, periodontal surgical wounds, and suture sites.
• MatrixMem™ A conformable and nonfriable regenerative collagen membrane for dental tissue regeneration procedures.
• MatrixOss™ Granules An osteoconductive, porous, anorganic bone mineral derived from porcine cancellous bone, used for dental bone grafting.
• SynOss™ Family Osteoconductive calcium phosphate-based bone graft material (granules, plug, and putty forms) offering a synthetic carbonate apatite alternative to human allograft and animal origin bone graft material.
• GUIDOR® Synthetic Bone Graft Products 100% synthetic bone graft substitute products including GUIDOR® calc-i-oss and GUIDOR® easy-graft that support bone regeneration and provide clot stability during initial healing.
• Collatene™ An absorbent microfibrillar collagen matrix used for management of oral wounds and sores.
• DuraMatrix® Family Collagen dural repair membranes (DuraMatrix®, DuraMatrix-Onlay®, DuraMatrix-Onlay® Plus, and DuraMatrix® Suturable) designed to optimize conformability and strength with high CSF leak resistance for cranial dural closure.
• LIQOSEAL® A dural sealant used as an adjunct to standard methods of cranial dural repair to provide a watertight closure of the dura mater and reduce CSF leakage.
• RejuvaKnee™ Meniscal Repair Implant A natural bovine-derived collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus; the first and only FDA-cleared regenerative implant device for meniscal repair.
• OssiMend® Bioactive Bone Graft Line Bioactive biocomposite matrices (moldable pucks, strips, pads, blocks, and putties) that are highly absorbent, flexible, compression-resistant, retain stem cells, and resorb during bone remodeling.
• TenoMend™ A resorbable type I collagen matrix that provides a non-constricting encasement for injured tendons in tendon repair procedures.
• Neuroflex® Nerve Conduit A flexible, collagen-based, kink-resistant nerve conduit ideal for reconstruction across nerve gaps spanning joints.
• NEUROLAC® Nerve Guide Synthetic nerve guides indicated for reconstruction of peripheral nerve discontinuities up to 20 mm.
• NEUROCAP® Nerve Capping Device A synthetic capping device intended for the surgical management of symptomatic end-neuromas.
• NeuroMatrix® Nerve Conduit A collagen-based conduit that alleviates tension at the repair site in straight gap peripheral nerve repair locations.
• NeuroMend Nerve Wrap A nerve wrap ideal for crush or compression injuries or partially severed nerves.
• VIVOSORB® Adhesion Prevention Film A flexible bioresorbable synthetic polymer film that separates opposing soft tissues post-surgery to prevent scar tissue and unintended adhesions.
• Regenerative Medical Device CDMO Services End-to-end contract development and manufacturing organization (CDMO) services providing R&D, material processing, prototype development, regulatory support, and commercial-scale manufacturing for regenerative medical devices, serving medtech partners from early feasibility through full commercialization.

Quantifiable outcome

• 30M+ patients impacted since founding
• +5 more outcomes

Named customers1 record

Segments8 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered core.

• MiMedx GroupcoreOEM/ Whitelabel/ Licensing Partner · 1 March 2024In March 2024, MiMedx Group entered into an exclusive manufacturing and supply agreement with Regenity Biosciences, granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications.
• PolyganicscoreStrategic or Co-development Partner · 5 October 2022Collagen Matrix (now Regenity) acquired Polyganics, a medical technology company specializing in synthetic polymer bioresorbable devices. The acquisition expanded Regenity's portfolio to include ENT and general surgery products while strengthening neurosurgery and peripheral nerve offerings. Polyganics' 75 employees joined Regenity.
• Sunstar / GUIDORcoreStrategic or Co-development Partner · 1 January 2020Collagen Matrix acquired Sunstar's Degradable Solutions division including the GUIDOR synthetic bone graft and membrane business. GUIDOR's synthetic technologies complement Collagen Matrix's proprietary collagen-based products, enabling a comprehensive regenerative medicine portfolio.
• GT Medical TechnologiescoreStrategic or Co-development PartnerGT Medical Technologies partnered with Regenity to bring GammaTile - a breakthrough in brain tumor treatment - to patients who need it most. Regenity's partnership supports the design and manufacturing of GammaTile therapy.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Geistlich Pharma: Swiss private company and the dominant global player in dental bone graft substitutes and barrier membranes (Bio-Oss, Bio-Gide) — the direct incumbent Regenity benchmarks its MatrixOss and Matrixflex products against in clinical studies.
• Integra LifeSciences: Public regenerative medical device company with overlapping portfolios in dural repair (DuraGen), nerve repair (NeuraGen, AxoGen-adjacent), and collagen-based wound matrices — directly comparable product categories in neurosurgery and nerve repair to Regenity's DuraMatrix and Neuroflex lines.
• MiMedx Group: Public regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications — Regenity's exclusive supply partner for collagen wound dressings under a March 2024 agreement, making it both customer and competitive comparable.
• DSM Biomedical (dsm-firmenich): Division of dsm-firmenich that supplies biomedical materials, including collagen, bioresorbable polymers, and coatings to the medical device industry — a directly comparable biomaterials CDMO/input supplier serving many of the same medtech OEMs.
• CollPlant Biotechnologies: Israel-based regenerative medicine company developing recombinant human collagen and regenerative tissue products for orthopedics, wound care, and 3D bioprinting — a closely comparable biomaterials platform with similar collagen-derived technology focus.
• Vericel: Public commercial-stage regenerative medicine company selling MACI (autologous chondrocyte implant for cartilage repair) and Epicel — comparable as a pure-play regenerative medicine business selling into orthopedics and wound care channels.
• MTF Biologics: Nonprofit tissue bank that develops and distributes allograft and regenerative tissue products for orthopedics, wound care, and sports medicine — a directly comparable regenerative biologics platform serving the same end markets.
• Organogenesis: Public regenerative medicine company focused on advanced wound care and surgical biologics (Apligraf, Dermagraft, NuShield) — directly comparable in wound care biologics and regenerative product positioning.

Broad incumbents

• Stryker: Large diversified medtech incumbent with orthopedics, spine, and surgical equipment portfolios that overlap Regenity's spine/orthopedic and ENT segments — competes broadly but does not specialize in collagen/synthetic-polymer regenerative biomaterials at Regenity's scale.
• Baxter International: Diversified medical products incumbent with surgical solutions, hemostats, and regenerative tissue products (e.g., Tisseel, Coseal) — broad incumbent that overlaps Regenity's surgical sealant (LIQOSEAL) and adhesion prevention (VIVOSORB) franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@regenity
• LinkedInlinkedin.com/company/regenity

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenity